Jump to content

Recommended Posts

Paul Edwards

Cabazitaxel is a chemotherapy treatment which is used when patients become resistant to chemotherapy treatment with Docetaxel.   Cabazitaxel improves overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with Docetaxel.

 

Androgen receptor splice variant 7 (AR-V7) in circulating tumuor cells (CTCs) from mCRPC patients was recently demonstrated to be associated with resistance to Abiraterone and Enzalutamide.

 

A group of Dutch and Belgian researchers investigated whether this was also true for Cabazitaxel.    They found that Cabazitaxel was effective even if AR-V7 was present.

 

Reference

"Efficacy of Cabazitaxel in Castration-resistant prostate cancer is independent of the presence of AR-V7 in Circulating Tumor Cells"   Wendy Ostenk et al
Article Information    DOI: 10.1016/j.eururo.2015.07.007

 

 

 

 

 

Share this post


Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.


×
×
  • Create New...